GSK PLC Sponsored ADR (NYSE:GSK) Given Consensus Recommendation of “Hold” by Brokerages

Shares of GSK PLC Sponsored ADR (NYSE:GSK) have been assigned an average recommendation of “Hold” from the ten ratings firms that are presently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $53.00.

A number of equities research analysts recently weighed in on GSK shares. Wall Street Zen cut shares of GSK from a “buy” rating to a “hold” rating in a research note on Saturday, May 30th. Weiss Ratings cut shares of GSK from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 11th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of GSK in a research note on Tuesday, June 9th.

GSK Price Performance

Shares of NYSE GSK opened at $50.76 on Tuesday. GSK has a fifty-two week low of $35.45 and a fifty-two week high of $61.69. The firm’s 50-day simple moving average is $52.66 and its 200 day simple moving average is $52.82. The company has a quick ratio of 0.52, a current ratio of 0.79 and a debt-to-equity ratio of 0.80. The stock has a market cap of $102.80 billion, a P/E ratio of 13.19, a P/E/G ratio of 2.62 and a beta of 0.36.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 9th. Investors of record on Friday, May 15th will be issued a dividend of $0.44 per share. This represents a $1.76 dividend on an annualized basis and a yield of 3.5%. The ex-dividend date of this dividend is Friday, May 15th. GSK’s payout ratio is presently 47.01%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of GSK. First Horizon Corp grew its holdings in GSK by 78.7% during the fourth quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock worth $26,000 after acquiring an additional 236 shares during the period. Elyxium Wealth LLC acquired a new position in GSK during the fourth quarter worth about $30,000. Triumph Capital Management acquired a new position in GSK during the third quarter worth about $40,000. 1248 Management LLC grew its holdings in GSK by 314.6% during the third quarter. 1248 Management LLC now owns 1,053 shares of the pharmaceutical company’s stock worth $46,000 after acquiring an additional 799 shares during the period. Finally, Coston McIsaac & Partners grew its holdings in GSK by 17.3% during the fourth quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company’s stock worth $68,000 after acquiring an additional 206 shares during the period. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.